Novel Case of Prader–Willi Syndrome and Ebstein's Anomaly: Implications for Complex Care Management

Abstract

We present a patient with a complex phenotype including diagnoses of Ebstein's anomaly and Prader–Willi syndrome (PWS) as well as additional congenital anomalies and genetic variants with potential clinical effects. This is the first reported case of both diagnoses present in the same patient. The diagnosis of Ebstein's anomaly was made on prenatal ultrasound. She presented with neonatal hypotonia, feeding problems, and dysmorphic features, followed by later onset weight gain, leading to a diagnosis of PWS. Further evaluations revealed Blaschkoid hyperpigmentation, laryngeal cleft, and pigmentary retinopathy. Whole exome sequencing determined a likely pathogenic variant in alkaline phosphatase gene and several mitochondrial DNA variants. We discuss the known genetic mechanisms of PWS and compare them to the heterogenous genetic associations of Ebstein's anomaly. The standard of care treatment for PWS is growth hormone therapy, which is associated with right-sided heart failure risks. This case illustrates the need to complete the diagnostic work up in all patients, as well as the necessity of a multidisciplinary approach for optimal outcomes.

Keywords

Prader–Willi - Ebstein's anomaly - Growth hormone - Blaschkoid hyperpigmentation

Publication History

Received: 21 October 2021

Accepted: 03 August 2022

Article published online:
10 October 2022

• References

• 1 Torrado M, Foncuberta ME, Perez MF. et al. Change in prevalence of congenital defects in children with Prader-Willi syndrome. Pediatrics 2013; 131 (02) e544-e549
• 2 Cassidy SB, Schwartz S, Miller JL, Driscoll DJ. Prader-Willi syndrome. Genet Med 2012; 14 (01) 10-26
• 3 Boyle B, Garne E, Loane M. et al. The changing epidemiology of Ebstein's anomaly and its relationship with maternal mental health conditions: a European registry-based study. Cardiol Young 2017; 27 (04) 677-685
• 4 Miller MS, Rao PN, Dudovitz RN, Falk RE. Ebstein anomaly and duplication of the distal arm of chromosome 15: report of two patients. Am J Med Genet A 2005; 139A [phone]
• 5 Benson DW, Silberbach GM, Kavanaugh-McHugh A. et al. Mutations in the cardiac transcription factor NKX2.5 affect diverse cardiac developmental pathways. J Clin Invest 1999; 104 (11) 1567-1573
• 6 Digilio MC, Bernardini L, Lepri F. et al. Ebstein anomaly: genetic heterogeneity and association with microdeletions 1p36 and 8p23.1. Am J Med Genet A 2011; 155A [phone]
• 7 Andelfinger G, Wright KN, Lee HS, Siemens LM, Benson DW. Canine tricuspid valve malformation, a model of human Ebstein anomaly, maps to dog chromosome 9. J Med Genet 2003; 40 (05) 320-324
• 8 Postma AV, van Engelen K, van de Meerakker J. et al. Mutations in the sarcomere gene MYH7 in Ebstein anomaly. Circ Cardiovasc Genet 2011; 4 (01) 43-50
• 9 Celermajer DS, Bull C, Till JA. et al. Ebstein's anomaly: presentation and outcome from fetus to adult. J Am Coll Cardiol 1994; 23 (01) 170-176
• 10 Grugni G, Sartorio A, Crinò A. Growth hormone therapy for Prader-Willi syndrome: challenges and solutions. Ther Clin Risk Manag 2016; 12: 873-881
• 11 Deal CL, Tony M, Höybye C, Allen DB, Tauber M, Christiansen JS. 2011 Growth Hormone in Prader-Willi Syndrome Clinical Care Guidelines Workshop Participants. GrowthHormone Research Society workshop summary: consensus guidelines for recombinant human growth hormone therapy in Prader-Willi syndrome. J Clin Endocrinol Metab 2013; 98 (06) E1072-E1087
• 12 Butler MG, Manzardo AM, Heinemann J, Loker C, Loker J. Causes of death in Prader-Willi syndrome: Prader-Willi Syndrome Association (USA) 40-year mortality survey. Genet Med 2017; 19 (06) 635-642
• 13 Freud LR, Escobar-Diaz MC, Kalish BT. et al. Outcomes and predictors of perinatal mortality in fetuses with Ebstein anomaly or tricuspid valve dysplasia in the current era: a multicenter study. Circulation 2015; 132 (06) 481-489
• 14 Seo GH, Yoo HW. Growth hormone therapy in patients with Noonan syndrome. Ann Pediatr Endocrinol Metab 2018; 23 (04) 176-181
• 15 Vandeleur M, Davey MJ, Nixon GM. Are sleep studies helpful in children with Prader-Willi syndrome prior to commencement of growth hormone therapy?. J Paediatr Child Health 2013; 49 (03) 238-241
• 16 Zimmermann M, Laemmer C, Woelfle J, Fimmers R, Gohlke B. Sleep-disordered breathing in children with Prader-Willi syndrome in relation to growth hormone therapy onset. Horm Res Paediatr 2020; 93 (02) 85-93
• 17 Miller J, Silverstein J, Shuster J, Driscoll DJ, Wagner M. Short-term effects of growth hormone on sleep abnormalities in Prader-Willi syndrome. J Clin Endocrinol Metab 2006; 91 (02) 413-417
• 18 Marzullo P, Marcassa C, Campini R. et al. Conditional cardiovascular response to growth hormone therapy in adult patients with Prader-Willi syndrome. J Clin Endocrinol Metab 2007; 92 (04) 1364-1371